A Phase 3 interventional study of flurbiprofen and placebo in Acute Pharyngitis and Sore Throat, sponsored by Reckitt Benckiser LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-28.
Sponsored by Reckitt Benckiser LLC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Pharyngitis with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Pharyngitis · United States.
Among the 41 studies in Pharyngitis with a site in United States, this one is the 27th largest by enrollment of the 35 interventional ones that give a count, is one of 5 that started in 2013, is one of 18 in phase 3, and was the 24th registered.
227 studies on the registry are indexed under Pharyngitis; 36 are open to participants now.
Browse Pharyngitis studies →4 of the 41 studies in Pharyngitis with a site in United States are open now. Recruiting first, the newest first:
SalivIQ Diagnostics, Inc. · Sites in United States
Ages 3+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 1 mo–99 yrs
University of Pittsburgh · Sites in United States
Ages 6 mo–24 mo
The University of Texas Health Science Center, Houston · Sites in United States
Ages 3–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 19 Pharyngitis studies recruiting now, 5 (26%) set no upper age limit and 10 (53%) stop at 75 or younger; 8 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 5 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 122 is below the median of 144 across 189 interventional studies indexed under Pharyngitis.
Median enrollment 204 across the 35 interventional studies, 587 across the 6 observational. Of the 33 that completed or were terminated, 13 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 41 have an industry lead sponsor. The 10 most frequent:
This study is registered under Reckitt Benckiser LLC, one of the names counted as Reckitt. Under that name alone:
Reckitt Benckiser LLC is the lead sponsor of 13 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Reckitt has 3 studies filed under Pharyngitis — fewer than ten, so there is no comparison to draw.
1 of the studies in Pharyngitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07891728SalivIQ Diagnostics, Inc.A Multicenter Evaluation of SalivIQ™ Strep A for Detecting Group A Streptococcus From Saliva and Throat Swabs in Patients With Acute Pharyngitis | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 41 studies in Pharyngitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study's purpose is to demonstrate the onset of action, i.e., time to meaningful pain relief in patients with pharyngitis, of flurbiprofen 8.75 mg lozenge using the Double-Stopwatch Method (DSW).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single flurbiprofen lozenge is sucked until fully dissolved.
Drug: flurbiprofen
A single placebo lozenge is sucked until fully dissolved.
Drug: placebo
A single flurbiprofen 8.75 mg lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
A single placebo lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
Kaplan-Meier Estimates for Time to Meaningful Pain Relief
Time to meaningful pain relief is a patient-reported outcome (PRO) captured as part of the double stopwatch method. Participants depress the second stop watch when they experience what they perceive as meaningful pain relief. Instructions to participants are: "Stop the second stopwatch when the sore throat pain relief is meaningful to you. This does not mean you feel completely better, although you might, but when you feel relief of throat pain that is meaningful to you." Participants who did not have perceived pain relief were censored at 3 hours.
Time frame: up to 3 hours post dose on Day 1
Kaplan-Meier Estimates for Time of First Perceived Pain Relief
Time to first perceived pain relief is a patient-reported outcome (PRO) captured as part of the double stopwatch method. Participants depress the first stop watch when they experience any pain relief, termed "perceived pain relief". Instructions to participants are: "Stop the first stopwatch when you first feel any sore throat pain relief whatsoever. This does not mean you feel completely better, although you might, but when you first feel any relief of the throat pain you have now." Participants who did not have perceived pain relief were censored at 3 hours.
Time frame: up to 3 hours post dose on Day 1
Kaplan-Meier Estimates for Time to First Perceived Pain Relief That Is Confirmed By Meaningful Pain Relief
Time to first perceived pain relief on the first stopwatch that was confirmed by meaningful pain relief on the second stopwatch. Participants who had no meaningful pain relief within 3 hours from baseline were censored to 3 hours.
Time frame: up to 3 hours post dose on Day 1
Kaplan-Meier Estimates for Time of First Indication of Sore Throat Relief as Measured By Any Reduction in the Sore Throat Scale (STS)
Time to first indication of sore throat relief, defined as any reduction or decrease in STS observed during the 3 hours post dose. Participants who did not have any reduction in STS from baseline within 3 hours were censored to 3 hours. The participant was asked to evaluate his/her sore throat when swallowing using a vertical 0-10 Likert scale, where 0=not sore and 10=very sore. The participant was instructed: "Circle the number that shows how sore your throat is now when you swallow." The STS was obtained at baseline, every 5 minutes after treatment during the first hour and every 10 minutes during the second and third hours.
Time frame: up to 3 hours post dose on Day 1
Kaplan-Meier Estimates for Time of First Perceived Pain Reduction on the Sore Throat Scale (STS) Which is Followed by ≥ 20% Pain Reduction on the Sore Throat Pain Intensity Scale (STPIS)
Time to pain reduction on the STS (defined as any reduction or decrease observed during the 3 hours post dose) for participants whose improvement was confirmed by a \>=20% reduction in pain on the STPIS. STS: The participant was asked to evaluate his/her sore throat when swallowing using a vertical 0-10 Likert scale, where 0=not sore and 10=very sore. The participant was instructed: "Circle the number that shows how sore your throat is now when you swallow." The STS was obtained at baseline, every 5 minutes after treatment during the first hour and every 10 minutes during the second and third hours. STPIS: The participant was instructed to swallow and: "Place a line on the Sore Throat Scale that best characterizes the severity of your sore throat now:" 0mm=no pain and 100mm=severe pain. The STPIS was obtained at baseline, after the participant depressed the second stopwatch, and at 1, 2, and 3 hours postdose.
Time frame: Baseline (Day 1, pre-dose), up to 3 hours post dose on Day 1
Change From Baseline at Individual Timepoints in Sore Throat Scale (STS)
The participant was asked to evaluate his/her sore throat when swallowing using a vertical 0-10 Likert scale, where 0=not sore and 10=very sore. The participant was instructed: "Circle the number that shows how sore your throat is now when you swallow." The STS was obtained at baseline, every 5 minutes after treatment during the first hour and every 10 minutes during the second and third hours.
Time frame: Baseline (Day 1, pre-dose), up to 3 hours post dose on Day 1
Percentage of Participants With Meaningful Pain Relief
Defined as the percentage of participants who pressed the second stopwatch during the 3 hour evaluation period.
Time frame: up to 3 hours post dose on Day 1
Percentage of Participants With Perceived Pain Relief
Defined as the percentage of participants who pressed the first stopwatch during the 3 hour evaluation period.
Time frame: up to 3 hours post dose on Day 1
Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Scale (STS) Over the 3 Hours Post-baseline (STS SPID3)
The participant was asked to evaluate his/her sore throat when swallowing using a vertical 0-10 Likert scale, where 0=not sore and 10=very sore. The participant was instructed: "Circle the number that shows how sore your throat is now when you swallow." STS was obtained at baseline, every 5 minutes after treatment during the first hour and every 10 minutes during the second and third hours, for a total of 24 post-dose measurements. The time-weighted SPID combines relief magnitude (PID = change from baseline) as weighted by duration interval between ratings. SPID3 refers to measurements taken up to 3 hours post-baseline, and has a full range of -1332 (complete pain relief within 5 minutes of dosing that lasts for 3 hours) to 468 (drug escalates level of pain to a score of 10 and the pain stays at that level for 3 hours) using the mean baseline STS value 7.4 for this study.
Time frame: Baseline (Day 1, pre-dose), up to 3 hours post dose on Day 1
| Milestone | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| Started | 101 | 21 |
| Completed | 101 | 21 |
| Not completed | 0 | 0 |
Time to meaningful pain relief is a patient-reported outcome (PRO) captured as part of the double stopwatch method. Participants depress the second stop watch when they experience what they perceive as meaningful pain relief. Instructions to participants are: "Stop the second stopwatch when the sore throat pain relief is meaningful to you. This does not mean you feel completely better, although you might, but when you feel relief of throat pain that is meaningful to you." Participants who did not have perceived pain relief were censored at 3 hours.
| minutes | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| Kaplan-Meier Estimates for Time to Meaningful Pain Relief | 42.917 (36.367 to 49.383) | NA (47.567 to NA) |
Time to first perceived pain relief is a patient-reported outcome (PRO) captured as part of the double stopwatch method. Participants depress the first stop watch when they experience any pain relief, termed "perceived pain relief". Instructions to participants are: "Stop the first stopwatch when you first feel any sore throat pain relief whatsoever. This does not mean you feel completely better, although you might, but when you first feel any relief of the throat pain you have now." Participants who did not have perceived pain relief were censored at 3 hours.
| minutes | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| Kaplan-Meier Estimates for Time of First Perceived Pain Relief | 10.867 (7.633 to 14.283) | 19.317 (4.783 to 30.333) |
Time to first perceived pain relief on the first stopwatch that was confirmed by meaningful pain relief on the second stopwatch. Participants who had no meaningful pain relief within 3 hours from baseline were censored to 3 hours.
| minutes | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| Kaplan-Meier Estimates for Time to First Perceived Pain Relief That Is Confirmed By Meaningful Pain Relief | 13.200 (8.633 to 16.567) | NA (6.633 to NA) |
Time to first indication of sore throat relief, defined as any reduction or decrease in STS observed during the 3 hours post dose. Participants who did not have any reduction in STS from baseline within 3 hours were censored to 3 hours. The participant was asked to evaluate his/her sore throat when swallowing using a vertical 0-10 Likert scale, where 0=not sore and 10=very sore. The participant was instructed: "Circle the number that shows how sore your throat is now when you swallow." The STS was obtained at baseline, every 5 minutes after treatment during the first hour and every 10 minutes during the second and third hours.
| minutes | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| Kaplan-Meier Estimates for Time of First Indication of Sore Throat Relief as Measured By Any Reduction in the Sore Throat Scale (STS) | 15.000 (10.000 to 15.000) | 20.000 (5.000 to 30.000) |
Time to pain reduction on the STS (defined as any reduction or decrease observed during the 3 hours post dose) for participants whose improvement was confirmed by a \>=20% reduction in pain on the STPIS. STS: The participant was asked to evaluate his/her sore throat when swallowing using a vertical 0-10 Likert scale, where 0=not sore and 10=very sore. The participant was instructed: "Circle the number that shows how sore your throat is now when you swallow." The STS was obtained at baseline, every 5 minutes after treatment during the first hour and every 10 minutes during the second and third hours. STPIS: The participant was instructed to swallow and: "Place a line on the Sore Throat Scale that best characterizes the severity of your sore throat now:" 0mm=no pain and 100mm=severe pain. The STPIS was obtained at baseline, after the participant depressed the second stopwatch, and at 1, 2, and 3 hours postdose.
| minutes | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| Kaplan-Meier Estimates for Time of First Perceived Pain Reduction on the Sore Throat Scale (STS) Which is Followed by ≥ 20% Pain Reduction on the Sore Throat Pain Intensity Scale (STPIS) | 15.000 (10.000 to 20.000) | NA (10.000 to NA) |
The participant was asked to evaluate his/her sore throat when swallowing using a vertical 0-10 Likert scale, where 0=not sore and 10=very sore. The participant was instructed: "Circle the number that shows how sore your throat is now when you swallow." The STS was obtained at baseline, every 5 minutes after treatment during the first hour and every 10 minutes during the second and third hours.
| units on a scale | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| Minute 5 | -0.4 ± 0.90 | -0.4 ± 0.67 |
| Minute 10 | -0.7 ± 1.14 | -0.6 ± 0.98 |
| Minute 15 | -0.9 ± 1.26 | -0.6 ± 0.87 |
| Minute 20 | -1.0 ± 1.30 | -0.6 ± 0.74 |
| Minute 25 | -1.3 ± 1.34 | -0.7 ± 0.90 |
| Minute 30 | -1.6 ± 1.41 | -1.0 ± 1.12 |
| Minute 35 | -1.8 ± 1.52 | -1.0 ± 1.20 |
| Minute 40 | -2.0 ± 1.50 | -1.1 ± 1.34 |
| Minute 45 | -2.2 ± 1.54 | -1.2 ± 1.36 |
| Minute 50 | -2.3 ± 1.59 | -1.3 ± 1.52 |
| Minute 55 | -2.4 ± 1.64 | -1.1 ± 1.49 |
| Minute 60 | -2.5 ± 1.69 | -1.1 ± 1.65 |
| Minute 70 | -2.6 ± 1.74 | -1.2 ± 1.72 |
| Minute 80 | -2.7 ± 1.85 | -1.1 ± 1.61 |
| Minute 90 | -2.7 ± 1.86 | -1.0 ± 1.77 |
| Minute 100 | -2.7 ± 1.87 | -1.0 ± 1.72 |
| Minute 110 | -2.7 ± 1.85 | -1.0 ± 1.83 |
| Minute 120 | -2.7 ± 1.91 | -1.0 ± 1.94 |
| Minute 130 | -2.6 ± 1.86 | -1.0 ± 1.83 |
| Minute 140 | -2.6 ± 1.95 | -0.9 ± 1.82 |
| Minute 150 | -2.5 ± 1.99 | -0.8 ± 1.97 |
| Minute 160 | -2.4 ± 2.01 | -0.9 ± 2.06 |
| Minute 170 | -2.3 ± 2.06 | -0.8 ± 2.23 |
| Minute 180 | -2.3 ± 2.05 | -0.8 ± 2.06 |
Defined as the percentage of participants who pressed the second stopwatch during the 3 hour evaluation period.
| percentage of participants | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| Percentage of Participants With Meaningful Pain Relief | 78.2 (70.2 to 86.3) | 47.6 (26.3 to 69.0) |
Defined as the percentage of participants who pressed the first stopwatch during the 3 hour evaluation period.
| percentage of participants | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| Percentage of Participants With Perceived Pain Relief | 97.0 (93.7 to 100.0) | 76.2 (58.0 to 94.4) |
The participant was asked to evaluate his/her sore throat when swallowing using a vertical 0-10 Likert scale, where 0=not sore and 10=very sore. The participant was instructed: "Circle the number that shows how sore your throat is now when you swallow." STS was obtained at baseline, every 5 minutes after treatment during the first hour and every 10 minutes during the second and third hours, for a total of 24 post-dose measurements. The time-weighted SPID combines relief magnitude (PID = change from baseline) as weighted by duration interval between ratings. SPID3 refers to measurements taken up to 3 hours post-baseline, and has a full range of -1332 (complete pain relief within 5 minutes of dosing that lasts for 3 hours) to 468 (drug escalates level of pain to a score of 10 and the pain stays at that level for 3 hours) using the mean baseline STS value 7.4 for this study.
| units on a scale | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Scale (STS) Over the 3 Hours Post-baseline (STS SPID3) | -403.9 (-457.3 to -350.5) | -166.4 (-286.8 to -46.0) |
Collected over up to 20 hours post dose. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Flurbiprofen 8.75 mg Lozenge | — | 0/101 (0%) | 10/101 (9.9%) |
| Placebo Lozenge | — | 0/21 (0%) | 1/21 (4.8%) |
| Event | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| HeadacheNervous system disorders | 1/101 | 1/21 |
| NauseaGastrointestinal disorders | 2/101 | 0/21 |
| PyrexiaGeneral disorders | 2/101 | 0/21 |
| Abdominal discomfortGastrointestinal disorders | 1/101 | 0/21 |
| DiarrhoeaGastrointestinal disorders | 1/101 | 0/21 |
| DizzinessNervous system disorders | 1/101 | 0/21 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/101 | 0/21 |
| Throat irritationRespiratory, thoracic and mediastinal disorders | 1/101 | 0/21 |
| Tonsillar hypertrophyRespiratory, thoracic and mediastinal disorders | 1/101 | 0/21 |
| Conjunctivitis infectiveInfections and infestations | 1/101 | 0/21 |
Randomized
| Age, Continuous(years) | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge | Total |
|---|---|---|---|
| Mean | 19.5 ± 2.02 | 19.6 ± 1.36 | 19.5 ± 1.92 |
| Sex: Female, Male(Participants) | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge | Total |
|---|---|---|---|
| Female | 58 | 13 | 71 |
| Male | 43 | 8 | 51 |
| Race/Ethnicity, Customized(Participants) | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 2 | 10 |
| Non-Hispanic or Non-Latino | 93 | 19 | 112 |
| Primary Race(Participants) | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge | Total |
|---|---|---|---|
| Asian | 2 | 0 | 2 |
| Black or African American | 3 | 2 | 5 |
| Multi-Racial | 2 | 0 | 2 |
| White | 94 | 19 | 113 |
| Weight(pounds) | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge | Total |
|---|---|---|---|
| Mean | 154.09 ± 31.221 | 154.19 ± 35.885 | 154.11 ± 31.913 |
| Height(inches) | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge | Total |
|---|---|---|---|
| Mean | 67.67 ± 4.187 | 66.90 ± 3.697 | 67.54 ± 4.103 |
| Sore Throat Scale (STS) Score(units on a scale) | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge | Total |
|---|---|---|---|
| Mean | 7.4 ± 0.97 | 7.3 ± 1.02 | 7.4 ± 0.98 |
| Sore Throat Pain Intensity Scale (STPIS)(units on a scale) | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge | Total |
|---|---|---|---|
| Mean | 73.8 ± 9.78 | 73.8 ± 9.64 | 73.8 ± 9.71 |
The record gives a start of Sep 2013, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2017, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Flurbiprofen